Discordant patient pain level reporting between questionnaires and physician encounters of the same day.

We examined the consistency of pain reporting by patients in a community pain management practice in Michigan. We compared pain levels (range 0-10) entered by patients in questionnaires versus those provided during their face-to-face physician encounter on the same day. Both of these values were available for approximately 10,000 encounters during the study period (2010-2014).

Patient-reported outcomes in a large community-based pain medicine practice: evaluation for use in phenotype modeling.

Background: An academic, community medicine partnership was established to build a phenotype-to-outcome model targeting chronic pain. This model will be used to drive clinical decision support for pain medicine in the community setting. The first step in this effort is an examination of the electronic health records (EHR) from clinics that treat chronic pain.

What determines age-related disease: do we know all the right questions?

The average human lifespan has increased throughout the last century due to the mitigation of many infectious diseases. More people now die of age-related diseases than ever before, but these diseases have been resistant to elimination. Progress has been made in treatments and preventative measures to delay the onsets of these diseases, but most cancers and vascular diseases are still with us and they kill about the same fraction of the population year after year.

A 17-year oscillation in cancer mortality birth cohorts on three continents - synchrony to cosmic ray modulations one generation earlier.

Cross-generational effects (grandmother effects) associated with epigenetic imprinting, environmental exposures, and lifestyle choices are beginning to be explored by various investigators. The possibility that low-level background radiation can be a driver of such effects has been suggested previously and is explored further in this study. Age-period-cohort analysis was performed on United States (US), United Kingdom (UK), and Australian (AU) female breast cancer mortality of the twentieth century, as well as on UK female total cancer mortality, to extract the high-frequency oscillations in the birth cohort time series.

Phase I study and preliminary pharmacology of the novel innate immune modulator rBBX-01 in gynecologic cancers.

Purpose: A recombinant protein product, rBBX-01, is the first innate immunostimulator derived from a protozoan (Eimeria protozoan) and has shown potent preclinical in vivo and in vitro activities. This phase I trial was done to determine the safety and basic pharmacology of rBBX-01.

Experimental Design: Eligible patients had recurrent incurable gynecologic malignancies.

Intestinal protozoa are hypothesized to stimulate immunosurveillance against colon cancer.

Colon cancer in humans results in considerable morbidity and mortality throughout most of the world. During the twentieth century, there was a rapid rise in colon cancer within modernizing countries that has not been adequately explained, although the role of diet has been widely explored. Previously, we showed that the presence of the endemic Eimeria spp.

Protein from intestinal Eimeria protozoan stimulates IL-12 release from dendritic cells, exhibits antitumor properties in vivo and is correlated with low intestinal tumorigenicity.

The small intestine (SI) of vertebrates exhibits low tumorigenesis and rarely supports metastatic growth from distant tumors. Many theories have been proposed to address this phenomenon, but none has been consistently supported. One candidate mechanism is that the vast immunologic compartment of the SI provides a heightened level of tumor immunosurveillance.